<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We recently reported an internal tandem duplication of the human flt3 receptor gene (FLT3) as a <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> in 17% of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The present study revealed the duplication at the juxtamembrane and the first tyrosine kinase domains of FLT3 in seven of 92 (8%) patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS), the diseases which may represent neoplastic changes of pluripotent stem cells </plain></SENT>
<SENT sid="2" pm="."><plain>A tandem duplication of exon 11 of FLT3 was harbored by two of 58 (3%) patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and five of 34 (15%) with overt <z:hpo ids='HP_0001909'>leukemia</z:hpo>, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS and therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Although the duplicated regions varied within exon 11 in each case, they occurred in-frame, and altered <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions were demonstrated by reverse-transcription polymerase chain reaction </plain></SENT>
<SENT sid="4" pm="."><plain>Two cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with a FLT3 duplication transformed to overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> within a few months </plain></SENT>
<SENT sid="5" pm="."><plain>Longitudinal analyses in two other patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> revealed that the duplication was a late genetic event during the disease course; one of whom showed two independent duplications of FLT3 at the terminal therapy-resistant phase </plain></SENT>
<SENT sid="6" pm="."><plain>Of seven patients with the FLT3 duplication, six had abnormal karyotypes, and four harbored a point mutation of the N-<z:mp ids='MP_0011356'>RAS</z:mp> and/or TP53 genes </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with FLT3 mutations have poor prognoses </plain></SENT>
<SENT sid="8" pm="."><plain>This study uncovered the fact that the accumulation of genetic events, including FLT3 duplication, correlates with leukemic transformation from antecedent <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and with subsequent disease progression </plain></SENT>
</text></document>